Cardinal Health: A Rebate Before There Was a Purchase

Cardinal Health purchase kickback settlements included $8 million over alleged pharmacy purchase payments in 2011 and $13,125,000 over upfront physician-practice discounts in 2022. Both pharmaceutical fraud cases concerned money paid to influence where customers bought their drugs. For someone who knows the purchasing contracts, the question is concrete: what purchase was that money supposed to pay back?

Cardinal is a pharmaceutical distributor based in Dublin, Ohio. It sells drugs into a business where the purchaser can also be the healthcare provider that bills a government program. The supplier’s payment to that purchaser is where these cases begin.

The 2011 Pharmacy Purchase-Payment Allegation

The earlier Cardinal Health settlement resolved an allegation that the distributor paid a pharmacy owner $440,000 in exchange for an agreement to buy prescription drugs from Cardinal. The Justice Department’s 2011 announcement described the payment.

A former pharmacy owner and a pharmacy consultant brought the qui tam case under the False Claims Act. The former owner alleged that he had received the payment himself. His account connected the money to the purchasing agreement from inside the transaction.

The government alleged that the payment violated the Anti-Kickback Statute. Its point was straightforward: kickbacks steer taxpayer money toward the provider’s pocket instead of patient care, while Medicare and Medicaid bear the cost.

The 2022 Physician Discounts Came Before the Purchases

The later settlement concerned upfront payments to physician practices that purchased specialty pharmaceuticals. In its January 31, 2022 announcement, the Justice Department said Cardinal acknowledged that customers received discounts not attributable to identifiable sales or purported rebates they had not actually earned.

The settlement agreement places the covered payments between February 2013 and January 2022. It describes them as upfront discounts, upfront rebates or transition rebates. The government’s allegation was that Cardinal paid practices before their pharmaceutical purchases to induce them to buy from Cardinal instead of competing distributors.

The agreement also explains how the drug purchases reached public money. Physician practices sought reimbursement from Medicare Part B and state Medicaid programs for specialty drugs their physicians administered to patients. The government contended that Cardinal’s payments caused false claims to be submitted to Medicare.

For the practice, the arrangement reached both sides of the business: money from the distributor and reimbursement for the administered drug. For a competing distributor, it affected the account before the orders arrived. The government alleged that Cardinal used the upfront money to win that purchasing decision.

Why Upfront Rebates Turn on the Purchase Behind Them

An upfront rebate can put money in a buyer’s hands before the purchases that supposedly earn it. The Cardinal announcement identifies the control that mattered: tying the amount to specific purchases and recovering it if the customer did not buy enough product to earn the discount.

The concern predates this settlement. In a July 17, 2000 letter about upfront rebates and signing bonuses, the HHS Office of Inspector General addressed medical-supply contracts under which sellers paid purchasers when contracts were signed. The described contracts required no refund if purchasers failed to meet minimum purchase requirements and could establish exclusive purchasing relationships.

The Inspector General’s office said the described payments were difficult to trace for proper disclosure and could lock purchasers into extended relationships, interfering with their normal cost and quality decisions. Cardinal’s later settlement applied the purchase-linkage problem to its own customer payments.

This is the practical question behind discount safe harbors: which sale earned the payment? Calling money a transition rebate supplies a label. The purchase records, calculation and handling of any unearned balance supply the explanation.

The Practice Buys the Drug and Bills for It

In the specialty-drug supply chain, the physician practice can be both a distributor’s customer and the health care provider seeking reimbursement. Cardinal’s agreement describes distribution to hospitals and practices, followed by practice claims for drugs administered to patients. That puts the purchasing relationship directly beside the government-paid treatment.

The practice also has an economic stake in the difference between acquisition and reimbursement. Medicare Part B ordinarily bases payment on average sales price with an add-on.

For an insider, this is why the amount on an invoice may leave an important question unanswered. The Cardinal allegations concerned money paid ahead of the orders. Understanding the account means connecting that payment with the purchases it was supposed to reward and the treatment for which the practice sought reimbursement.

How Do Pharmaceutical Kickbacks Work?

In these cases, the alleged pharmaceutical kickback was a supplier’s payment to win drug purchases that government health programs would pay for. The benefit could reach the customer before a single order did.

Other pharmaceutical kickback cases show how the benefit can take a different form. ASD Specialty Healthcare, doing business as Besse Medical, agreed to a $1.67 million settlement in December 2024 over allegations that it supplied free PODIS inventory management systems to induce drug purchases.

An inventory system is useful to a customer in a way that an upfront payment is useful: the supplier gives the buyer something of value to secure the drug business. That is the shared allegation. It directs attention to what the customer received in return for its purchasing choices, whether the benefit appears in a cash transfer or equipment used in the practice.

What Evidence Is Needed to Prove Fraud?

For a purchase-incentive case, the evidence connects the payment, the promised purchases, what the customer actually bought and the resulting government claims.

We connect purchasing contracts, payment records, invoices, rebate calculations and reimbursement records to show what the customer received and what the government paid for.

Those records tell a more complete story together. The purchasing employee may understand the commitment, the account manager may know why the payment was offered, and someone handling rebates may see whether the customer ever reached the required purchases. We work with pharmaceutical whistleblowers to connect that knowledge to the transaction and the claims it affected.

How Much Money Do Pharmaceutical Whistleblowers Get for Exposing Fraud?

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. In Cardinal’s later resolution, the Justice Department announced a whistleblower share of approximately $2.6 million of the recovery.

Whistleblowers brought both Cardinal cases. In the pharmacy case, the people who brought the case knew the purchasing business from the owner’s and consultant’s sides. Their roles show why a useful account can come from someone who understands the customer relationship as well as from someone inside the distributor.

You Know What the Customer Had to Buy

You know why a practice received money before placing its orders. Speak with our whistleblower experts about what that money bought. We build your strongest pharmaceutical kickback whistleblower case around the purchasing decisions and records you understand, bring in whistleblower lawyers who know distributor rebate cases, and stay beside you through the pursuit of a recovery.